innovative genetic medicines and drug delivery systems. The company is involved in life sciences R&D and engineering, contributing to advancements in genetic medicine. Evercrisp Biosciences designs receptor-targeted miniproteins to enable precise, non-viral delivery of gene editing tools to difficult-to-reach tissues such as the brain, kidney, and muscle. Their platform also incorporates endosomal escape elements to improve delivery efficiency and supports collaborations for developing tissue-specific therapeutic payloads.